Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Abstract Background Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to...

Полное описание

Библиографические подробности
Главные авторы:	Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng
Формат:	Статья
Язык:	English
Опубликовано:	BMC 2023-09-01
Серии:	BMC Cancer
Предметы:	Breast cancer Estrogen receptor Neoadjuvant chemotherapy Pathologic complete response Prognosis
Online-ссылка:	https://doi.org/10.1186/s12885-023-11368-2

Схожие документы

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
по: He Dou, и др.
Опубликовано: (2024-01-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
по: I.P.C. Buzatto, и др.

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
по: Yingbo Shao, и др.
Опубликовано: (2025-03-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
по: Yingbo Shao, и др.
Опубликовано: (2024-02-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
по: In Hee Lee, и др.
Опубликовано: (2020-11-01)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
по: Jin Hong, и др.
Опубликовано: (2021-11-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
по: Lingfeng Tang, и др.
Опубликовано: (2024-05-01)

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer
по: Shan Fang, и др.
Опубликовано: (2024-02-01)

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
по: Zhendong Shi, и др.
Опубликовано: (2024-07-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
по: Yoshitaka Shimamaki, и др.
Опубликовано: (2024-02-01)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
по: Elina Sivina, и др.
Опубликовано: (2023-03-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
по: Shuling Zhou, и др.
Опубликовано: (2023-02-01)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
по: Mengping Long, и др.
Опубликовано: (2022-12-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
по: Ling-Ming Tseng, и др.
Опубликовано: (2023-12-01)

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study
по: Zhaoyue Zhou, и др.
Опубликовано: (2023-01-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
по: Qing Hu, и др.
Опубликовано: (2021-06-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
по: Mina M. G. Youssef, и др.
Опубликовано: (2021-02-01)

Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis
по: Yue Guo, и др.
Опубликовано: (2025-02-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
по: Sungchan Gwark, и др.
Опубликовано: (2021-09-01)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
по: Cui Jiang, и др.
Опубликовано: (2019-09-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
по: Witali Aswolinskiy, и др.
Опубликовано: (2023-11-01)

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer
по: Zuhat Urakçı, и др.
Опубликовано: (2023-10-01)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
по: Li-Yun Xie, и др.
Опубликовано: (2022-04-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
по: Lingfeng Tang, и др.
Опубликовано: (2022-12-01)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
по: Ruo-Xi Wang, и др.
Опубликовано: (2022-10-01)

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
по: Samuel Rosner, MD, и др.
Опубликовано: (2022-09-01)

Imaging‐proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer
по: Jingxian Duan, и др.
Опубликовано: (2023-12-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
по: Jung Hwan Ji, и др.
Опубликовано: (2023-01-01)

Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China
по: Shaorong Zhao, и др.
Опубликовано: (2024-05-01)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
по: Pingping Liu, и др.
Опубликовано: (2022-04-01)

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
по: P. V. Krivorotko, и др.
Опубликовано: (2022-12-01)

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
по: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Опубликовано: (2023-07-01)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
по: Changfang Fu, и др.
Опубликовано: (2021-08-01)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
по: Yanhua Chen, и др.
Опубликовано: (2020-03-01)

A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
по: Amina Maimaitiaili, и др.
Опубликовано: (2024-05-01)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
по: Yushi Liu, и др.
Опубликовано: (2022-06-01)

Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features
по: Pingjuan Ni, и др.
Опубликовано: (2025-03-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
по: Lucas MW, и др.
Опубликовано: (2022-08-01)

Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model
по: Xiaodan Feng, и др.
Опубликовано: (2025-02-01)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
по: Sarah L. Savaridas, и др.
Опубликовано: (2019-10-01)